Achieving TGA medical device compliance

For a medical device manufacturer seeking to supply products in Australia, TGA compliance is not a single approval event. It is a regulatory system that extends from determining whether a product is a medical device through classification, conformity assessment, evidence generation, Australian Register of Therapeutic Goods (ARTG) inclusion and ongoing post-market responsibilities.

The Therapeutic Goods Administration (TGA) regulates medical devices under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002. The framework is risk-based, meaning the regulatory pathway depends on the characteristics, intended purpose and risks associated with the device.

Achieving compliance therefore requires more than preparing an application. The manufacturer needs a controlled body of technical, quality and regulatory evidence that demonstrates the device continues to meet the applicable requirements throughout its lifecycle.

Start with the intended purpose

The intended purpose is fundamental to medical device regulation because it influences whether a product falls within the medical device definition and, where it does, how it is classified.

The TGA states that manufacturers are responsible for classifying their medical devices and that the intended purpose is critical to determining the correct classification. The same device can potentially have a different classification depending on how it is intended to be used, including factors such as the part of the body involved and whether the device is intended for use by healthcare professionals or consumers.

This makes intended-purpose documentation an important starting point. The description should be sufficiently precise to support consistent interpretation across regulatory documentation, labelling, technical documentation and other controlled information.

A poorly defined intended purpose can create downstream problems because classification, evidence requirements and conformity assessment depend on the characteristics and intended use of the device.

Determine the correct classification

Australia uses a risk-based classification system for medical devices. For conventional medical devices, classifications include Class I, Class IIa, Class IIb and Class III, with increasing regulatory oversight associated with higher-risk classifications. Different classification rules apply depending on the nature and intended purpose of the device.

Classification is not simply an administrative step. It determines the regulatory pathway and the level of evidence and conformity assessment required before supply.

Manufacturers need to apply the relevant classification rules systematically and document the reasoning supporting the selected class. For devices with multiple functions or characteristics, more than one classification rule may be relevant. The applicable rules therefore need to be considered collectively rather than selecting a classification based on a single characteristic.

For a manufacturer preparing for Australian market entry, establishing the classification early can prevent substantial rework later in the regulatory process.

Demonstrate compliance with the Essential Principles

Medical devices supplied in Australia must comply with the Essential Principles. These are legislative requirements addressing fundamental aspects of medical device safety and performance and are set out in Schedule 1 of the Therapeutic Goods (Medical Devices) Regulations 2002.

The Essential Principles cover matters including design and construction, intended purpose, safety and performance, and other requirements relevant to the device.

Manufacturers must hold scientific and other evidence demonstrating that their devices meet the applicable Principles before the devices can be supplied in Australia. Sponsors must either hold that evidence or be able to obtain it from the manufacturer when required.

Compliance should therefore be supported by objective evidence rather than statements of intent. Depending on the device, this may involve design documentation, risk management records, verification and validation results, clinical evidence, performance data, manufacturing information, labelling and other technical documentation.

The evidence should be traceable to the applicable requirements and maintained under appropriate document and record controls.

Apply the appropriate conformity assessment procedure

Conformity assessment is a central component of Australian medical device regulation. The TGA describes it as the systematic and ongoing examination of evidence and procedures used to determine whether a medical device is acceptable in terms of safety and performance and conforms to the Essential Principles.

The required conformity assessment pathway depends on the device and its associated risks. Lower-risk devices may be eligible for manufacturer self-assessment in circumstances specified by the regulations, whereas higher-risk devices can require assessment of the manufacturer's quality management system and examination of device-specific design information by an appropriate conformity assessment body.

The manufacturer must therefore understand which conformity assessment procedure applies before attempting to establish the regulatory evidence package.

For some devices, appropriate overseas conformity assessment evidence may be used under the Australian regulatory framework. The suitability of overseas evidence depends on the applicable Australian requirements and the evidence pathway available for the device.

Establish a functioning quality management system

A compliant medical device cannot be separated from the processes used to design, manufacture and control it.

Quality management arrangements need to provide appropriate control over activities such as document management, design and development where applicable, production, supplier controls, nonconforming product, corrective action, change management, complaints and records.

The exact quality management requirements depend on the device, manufacturing activities and applicable conformity assessment procedure. The important principle is that the quality system should provide objective evidence that controlled processes are actually operating as intended.

This distinction matters during audits. Having a procedure is not equivalent to demonstrating that the procedure is implemented effectively. Records, approvals, training evidence, monitoring activities and other objective evidence need to support the documented system.

Build an evidence-based technical file

Regulatory compliance depends on evidence being available and maintained.

The TGA requires manufacturers to maintain evidence supporting compliance with the Essential Principles. The evidence needs to be appropriate to the device and its regulatory pathway.

A technical documentation system should allow the manufacturer to establish a clear relationship between requirements, identified risks, design specifications, verification and validation activities, clinical or performance evidence and the final device.

Risk management is particularly important because it provides a structured method for identifying hazards, evaluating risks and determining appropriate controls. The TGA's Essential Principles guidance specifically addresses the need for manufacturers to identify hazards and associated risks arising from intended use and foreseeable misuse and to apply appropriate risk controls.

Technical evidence should also remain current when the device changes. A modification to hardware, software, materials, manufacturing processes, suppliers or intended use may affect existing evidence and require an assessment of regulatory consequences.

Understand the role of the Australian sponsor

The sponsor has a distinct role in the Australian regulatory system. Medical devices generally need to be included in the ARTG before they can be supplied, imported or exported in Australia, and the Australian sponsor is responsible for the ARTG application.

The sponsor also needs an effective relationship with the manufacturer. This is important because the sponsor must be able to meet its regulatory obligations and obtain relevant information from the manufacturer when required.

For overseas manufacturers, this relationship should be supported by clear arrangements governing regulatory information, technical documentation, changes, complaints, adverse events and other information relevant to maintaining compliance.

Obtain ARTG inclusion

Once the applicable regulatory requirements and manufacturer evidence have been addressed, the device can proceed through the relevant ARTG inclusion process.

The evidence required depends on the device and its classification. The TGA requires appropriate Manufacturer's Evidence for relevant medical device applications, while some lower-risk devices have specific self-declaration pathways.

An ARTG inclusion should not be regarded as the end of the compliance process. The regulatory framework extends beyond market entry and includes continuing compliance with regulatory, safety and performance requirements.

Maintain compliance after market entry

Post-market compliance is an essential part of maintaining a medical device on the Australian market.

Manufacturers and sponsors need processes for monitoring device performance, managing complaints, identifying potential safety issues, assessing reportable events where applicable, implementing corrective actions and maintaining relevant regulatory evidence.

Changes also require controlled assessment. A manufacturer should not assume that a modification is insignificant simply because the physical change appears minor. The potential effect on safety, performance, intended purpose, classification, conformity assessment and existing evidence needs to be considered.

Maintaining compliance therefore requires an effective change-control process connected to the regulatory and technical documentation system.

Prepare for regulatory scrutiny

TGA compliance should be designed so that evidence can be retrieved, understood and defended when required.

This means avoiding documentation that exists only to satisfy an application checklist. A robust system should allow an organisation to demonstrate how it identified applicable requirements, assessed risks, generated evidence, controlled manufacturing activities and responded to information obtained after market entry.

Internal audits can provide an important mechanism for testing whether the system works in practice. They can examine whether procedures remain appropriate, whether records demonstrate implementation and whether corrective actions have been effective.

Regular review also helps identify gaps before they become significant regulatory problems.

Compliance is a lifecycle activity

Achieving TGA medical device compliance requires coordinated control of classification, Essential Principles, conformity assessment, technical evidence, quality systems, ARTG requirements and post-market activities.

The central objective is not simply to obtain an ARTG entry. It is to establish and maintain evidence that the device remains safe, performs as intended and continues to meet the applicable regulatory requirements.

For manufacturers, this means integrating regulatory requirements into product development, quality management and operational decision-making. When regulatory evidence, quality processes and technical controls are maintained as an interconnected system, compliance becomes an ongoing organisational capability rather than a project completed immediately before market entry.